Pamela McShane is a Respiratory physician. OpenAlex indexes 102 publications with 2,162 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11937 Us Highway 271
Tyler, TX 757083154
Telephone
903-877-7200Provider last certified this registry record 2 Jan 2024.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20259 payments
- Insmed, Inc.Program year20251 payment
- HOSPIRA, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
72.9%Macrolide Antimicrobial20.8%Azithromycin100%Part D≥106 patientsAntimycobacterial18.1%Ethambutol Hcl100%Part D≥87 patients+ 9 more classes in this area
Respiratory
17.2%Corticosteroid8.2%Trelegy Ellipta74%Fluticasone Propionate10%Arnuity Ellipta9%Breo Ellipta6%Part D<11 patientsbeta2-Adrenergic Agonist6.7%Albuterol Sulfate Hfa79%Ventolin Hfa21%Part D≥49 patients+ 2 more classes in this area
Sensory organs
4.6%Aminoglycoside Antibacterial3.8%Gentamicin Sulfate100%Part D≥28 patientsFluoroquinolone Antibacterial0.7%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
New England Journal of Medicine
2025 - European Respiratory Society clinical practice guideline for the management of adult bronchiectasis
European Respiratory Journal
2025 - Culture and real-time quantitative PCR to detect environmental nontuberculous mycobacteria in a clinical care center
Total Environment Microbiology
2025 - Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”